MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.
Amid COVID-19, Lower Cancer Diagnosis Rates Mean Fewer Patients Getting Molecular Tests, Treatment
Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.
Genetron Health Obtains Regulatory Approval in China for NGS Instrument, Lung Cancer Panel
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
Colon Cancer Biomarker Undertesting Rates in Real-World Data Points to Precision Oncology Barriers
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.